Health
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia
This is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs inChina. ARVN003 is expected to be the first approved drug for presbyopia inChina. SHANGHAI, July 4, 2022 /PRNew...
2022-07-04 22:14
2365
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first high...
2022-07-04 13:34
2013
ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment ofPaul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our team," s...
2022-07-01 22:00
5051
Bon Natural Life Limited Announces Change to Board Composition
XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment ofJeffrey Guzy, as a new independent Director to i...
2022-07-01 04:30
3233
Fosun's Businesses Shows Strong Recovery Momentum as Consumption Regains Vitality and Tourism Industry Continues to Recover
HONG KONG, June 30, 2022 /PRNewswire/ -- The Bund Finance Center (BFC) in Shanghai officially resumed dine-in services at restaurants starting from 29 June. At present, Fosun's businesses and shopping centers inShanghai, including the BFC, Yuyuan Tourist Mart, Forte Woli City, and Orstar City Zhe...
2022-06-30 20:16
3861
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
SUZHOU, China and ROCKVILLE, Md., June 29, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm...
2022-06-30 10:41
1678
Infobird Co., Ltd Provides Digital and Intelligent Customer Engagement Solution to Enhance Patient Vaccination Notification Services for a Top-10 Global Pharmaceutical Company's Subsidiary
BEIJING, June 29, 2022 /PRNewswire/ -- Infobird Co., Ltd (NASDAQ: IFBD) ("Infobird" or the "Company"), a leading provider of AI-powered customer engagement solutions inChina, today announced that it has started to provide services to a leading global pharmaceutical and vaccine manufacturer's sub...
2022-06-29 20:30
2014
Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
* Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing * China's first immunotherapy bi-specific antibody approved for marketing * A phase III trial of Cadonilimab combined with platinum-based chemotherapy +/- bevacizumab for the first-line treatment ...
2022-06-29 20:14
1941
Supporting Communities and Sharing Happiness, 28 Liberty Successfully Hosts Multiple Community Events at New York's Fosun Plaza
NEW YORK, June 28, 2022 /PRNewswire/ -- As the summer arrives, New Yorkers have been enjoying their favorite season in the year. Starting from early June, in just 3 weeks, Fosun's 28 Liberty has successfully hosted multiple community events at Fosun Plaza with thousands of participants, in suppor...
2022-06-29 09:00
1723
iNtRON to Seek a New Clinical Partner for SAL200 Endolysin
* TONABACASE, the first registered INN by WHO for Endolysin * First-in-Class Endolysin-based Drug against Superbugs * US FDA Phase 2 IND Approval for TONABACASE, SAL200 * Roivant has returned the rights for the asset just before the first patient injection BOSTON and SEOUL, South Korea, Jun...
2022-06-28 21:00
1665
Sanofi Enters into a Partnering Agreement with Health2Sync
Paving the Way for Digital Therapeutics in Diabetes TAIPEI and TOKYO, June 27, 2022 /PRNewswire/ -- Sanofi K.K. (Head office: Shinjuku-ku,Tokyo; President: Takahiko Iwaya; hereinafter "Sanofi") and Health2Sync. (Head office: Taito-ku,Tokyo; CEO: Ed Deng) have entered into a partnering agreement ...
2022-06-28 11:00
1885
Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the B7H4x4-1BB bispecific antibody (HBM7008), whi...
2022-06-27 19:04
2369
Amcor Lift-Off initiative shortlists start-ups for seed funding
ZURICH, June 27, 2022 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced the next phase of its inauguralAmcor Lift-Off initiative. Announced in April, Amcor Lift-Off is part of the organization's global innova...
2022-06-27 17:03
1977
Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application
SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the acceptance nu...
2022-06-26 08:00
3623
Sanyou Biopharmaceuticals forged strategic partnership with Dragon Sail Pharmaceutical to upgrade integrated innovative antibody drug R&D
SHANGHAI, June 24, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals, a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, aCDMO and CMO enterprise dedicated to providing world-leading high-end biological drug manufacture servic...
2022-06-25 08:00
4962
Stryker's debut at World Intelligence Congress: Bringing Stryker's Advanced Digital Healthcare to China
SHANGHAI, June 24, 2022 /PRNewswire/ -- Stryker (NYSE:SYK), a leading medical technologies company, attended the 6th World Intelligence Congress (WIC) in China, showcasing how its Advanced Digital Healthcare solutions brings clinical, operational and financial values for the healthcare market. Th...
2022-06-24 23:00
5623
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patients with idiopathic pulmonary fibrosis - Daewoong Pharmaceutical to start a multinational phase 2 clinical trial for DWN12088 in September SEOUL, South Korea, June 24, 2022 /PRNewswire/ -- Daewoong...
2022-06-24 21:00
3551
USANA Malaysia Named No. 1 Combination Dietary Supplements Brand by Euromonitor International
Euromonitor International honors USANA Malaysia for fourth year in a row KUALA LUMPUR, Malaysia, June 24, 2022 /PRNewswire/ -- USANA Malaysia was recently recognized as a top brand by market research giant Euromonitor International. Awarded the title No. 1 Combination Dietary Supplements Brand in...
2022-06-24 10:00
5708
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian Medicin...
2022-06-23 23:00
2312
Viva Biotech Successfully Held The 3rd Annual Partnership Summit
SHANGHAI, June 23, 2022 /PRNewswire/ -- June 16th-20th, 2022 (Beijing time), Viva Biotech 2022 Partnership Summit was successfully held. Over 300 attendees joined the Summit, including founders from portfolio companies, representatives from global investment institutions, R&D heads from pharmaceu...
2022-06-23 20:30
2207
Week's Top Stories
Most Reposted
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
[Picked up by 350 media titles]
2024-09-18 11:30
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 315 media titles]
2024-09-16 11:50
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
[Picked up by 283 media titles]
2024-09-19 14:00
Watsons-Marlow unveils Qdos™ H-FLO and WMArchitectTM :Innovating fluid solutions for the chemical and biopharmaceutical industries respectively
[Picked up by 274 media titles]
2024-09-19 08:00
MediSun Energy Teams Up with EEIC to Strengthen UAE's Water Security and Advance Sustainable Energy Solutions
[Picked up by 267 media titles]
2024-09-18 09:15
Most Read
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
2024-09-18 11:30
11902
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
2024-09-16 11:50
9855
MediSun Energy Teams Up with EEIC to Strengthen UAE's Water Security and Advance Sustainable Energy Solutions
2024-09-18 09:15
7920
Watsons-Marlow unveils Qdos™ H-FLO and WMArchitectTM :Innovating fluid solutions for the chemical and biopharmaceutical industries respectively
2024-09-19 08:00
7614
Foton Motor & ZF: Hybrid Cooperation For Greener, advanced Commercial Vehicles
2024-09-18 10:37
7005
